Align Technology (ALGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$159.37-3.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · ALGN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks ALGN against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 67% of the last 6 guided quarters · 6.5% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Disciplined expense management and productivity improvements contributed to non-GAAP operating margin of 24.4%, above our outlook.
Stated in 5 of 8 supplied quarters. Management reported: “Disciplined expense management and productivity improvements contributed to non-GAAP operating margin of 24.4%, above our outlook.” “For fiscal 2027, we currently expect GAAP and non-GAAP operating margins to increase at least approximately 100 basis points year-over-year.” Operating income was $169.164 million in 2026-Q3.
“Disciplined expense management and productivity improvements contributed to non-GAAP operating margin of 24.4%, above our outlook.”
“For fiscal 2027, we currently expect GAAP and non-GAAP operating margins to increase at least approximately 100 basis points year-over-year.”
“We expect the impact of foreign exchange to moderate in the remaining quarters, trending toward the full year assumption of approximately 100 basis points • We expect 2026 Clear Aligner volume growth…”
“We expect these restructuring actions, as well as other initiatives, to improve our GAAP and non-GAAP operating margins by at least 100 basis points year-over-year - 5 - Align Technology Announces Th…”
“• We expect fiscal 2025 GAAP operating margin to be approximately 2 points above 2024 GAAP operating margin, and we expect 2025 non-GAAP operating margin to be approximately 22.5%, which both reflect…”
• We expect to repurchase approximately $500M of our common stock in 2026, reflecting the conviction of the Board and Management in Align's long-term value.
Stated in 3 of 8 supplied quarters. Management reported: “• We expect to repurchase approximately $500M of our common stock in 2026, reflecting the conviction of the Board and Management in Align's long-term value.” “Under the new program, Align may purchase up to $1.0 billion of its common stock over the next three years.”
“• We expect to repurchase approximately $500M of our common stock in 2026, reflecting the conviction of the Board and Management in Align's long-term value.”
Our focus remains on expanding iTero’s reach and in Q3, the number of scanner units placed, including leased, rented and certified pre-owned systems increased double-digits year-over-year, to more th…
Stated in 3 of 8 supplied quarters. Management reported: “Our focus remains on expanding iTero’s reach and in Q3, the number of scanner units placed, including leased, rented and certified pre-owned systems increased double-digits year-over-year, to more than 157,000 systems globally.” “As we move forward in 2026, our focus is on maintaining discipline as we strategically invest in innovation and growth opportunities, including advancing digital dentistry through the Align™ Digital Platform, scaling our iTero Lumina ecosystem, expanding internationally with localized strategies, and continuing to build a differentiated portfolio for teens and growing patients."”
Overall, Q3 demonstrated continued Clear Aligner growth, expansion of our digital platform and customer footprint, and improved profitability."
Stated in 4 of 8 supplied quarters. Management reported: “Overall, Q3 demonstrated continued Clear Aligner growth, expansion of our digital platform and customer footprint, and improved profitability."” “However, we remain laser focused on executing our strategic plan for profitable revenue growth across our two operating segments.” Revenue was $1.015 billion in 2026-Q3.
“Overall, Q3 demonstrated continued Clear Aligner growth, expansion of our digital platform and customer footprint, and improved profitability."”
Fund technology upgrades, additional manufacturing capacity, and maintenance within the stated 2026 capital expenditure range.
Over the trailing year it converted 0.64x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Most sensitive to the broad stock market and long-term interest rates.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“• We now expect to repurchase $400 million to $500 million of our common stock in 2026, reflecting the conviction of the Board and Management in Align's long-term value.”
“Under the new program, Align may purchase up to $1.0 billion of its common stock over the next three years.”
“Our focus remains on expanding iTero’s reach and in Q3, the number of scanner units placed—including leased, rented and certified pre-owned systems increased double-digits year-over-year, to more tha…”
“Every digital workflow begins with a scan, making scanner adoption important driver to increasing patient access to orthodontic care and long-term platform growth.”
“As we move forward in 2026, our focus is on maintaining discipline as we strategically invest in innovation and growth opportunities, including advancing digital dentistry through the Align™ Digital…”
“However, we remain laser focused on executing our strategic plan for profitable revenue growth across our two operating segments.”
“(1) Commenting on Align's Q1'26 results, Align Technology President and CEO Joe Hogan said, “We’re pleased to report another better-than-expected quarter, with Q1’26 revenues, Clear Aligner volumes,…”
“Our confidence is grounded in the actions we’re taking to actively manage the business and drive growth through our core strategic priorities — expanding international adoption, increasing orthodonti…”